This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AcelRx Pharmaceuticals (ACRX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 26.09% and -68.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)
by Zacks Equity Research
Does AcelRx Pharmaceuticals (ACRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ACRX) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.00% and -65.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will AcelRx Pharmaceuticals (ACRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
by Zacks Equity Research
AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.
Are Options Traders Betting on a Big Move in AcelRx Pharmaceuticals (ACRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ACRX) Outperforming Other Medical Stocks This Year?
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.26% and -11.57%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
by Zacks Equity Research
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
Pacira (PCRX) Issues Strong Preliminary Exparel Sales for Q2
by Zacks Equity Research
Pacira (PCRX) announces robust preliminary results for Exparel sales in second quarter on the back of increasing adoption for pain management in surgical procedures.
VIVUS' PAH Candidate Data Positive in Early Stage Study
by Zacks Equity Research
VIVUS' (VVUS) pipeline candidate, VI-0106, shows positive activity in a preliminary analysis of phase I study in patients with pulmonary arterial hypertension.
Aclaris' Alopecia Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
Top Ranked Momentum Stocks to Buy for June 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 25th:
Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
by Zacks Equity Research
Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.
Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy
by Kinjel Shah
Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.
Top Ranked Momentum Stocks to Buy for June 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 15th:
Top Ranked Momentum Stocks to Buy for June 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 8th: